Fibrinogen Deficiency

Human Fibrinogen - Pharmacokinetics
NCT00496262 | PHASE 2 | INTERVENTIONAL

This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness \[MCF\]) in subjects with congenital fibrinogen deficiency. MCF was measured to demonstrate the functional activity of replacement fibrinogen when a fixed dose of human fibrinogen concentrate was administered.

Trial Information
15 Sites
15 Participants
Recruiting
6 Years to 45 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Contact CSL Behring for facility details
Aurora,Colorado,United States,80045
Contact CSL Behring for facility details
St. Petersburg,Florida,United States,33701
Contact CSL Behring for facility details
Chicago,Illinois,United States,60614
Contact CSL Behring for facility details
Scarborough,Maine,United States,04074
Contact CSL Behring for facility details
New York,New York,United States,10021
Contact CSL Behring for facility details
Pittsburgh,Pennsylvania,United States,15232
Contact CSL Behring for facility details
Cagliari,Italy,09100
Contact CSL Behring for facility details
Firenze,Italy,50134
Contact CSL Behring for facility details
Milano,Italy,20122
Contact CSL Behring for facility details
Napoli,Italy,80122
Contact CSL Behring for facility details
Padova,Italy,35128
Contact CSL Behring for facility details
Palermo,Italy,90134
Contact CSL Behring for facility details
Rome,Italy,00161
Contact CSL Behring for facility details
Sassari,Italy,07100
Contact CSL Behring for facility details
Vicenza,Italy,36100

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov